Apotex Inc. (Canada) holds 50 active US FDA Type II Drug Master Files and 2 inactive, has DMF or CEP filings on record for 40 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 1 FDA-registered manufacturing site. 50 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Apotex Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/apotex-inc

Overview

Apotex Inc. is a Canadian pharmaceutical company that produces a wide range of affordable and high-quality generic medications. It is a leader in research and development of innovative pharmaceutical solutions.

Core services & business areas

Generic PharmaceuticalsResearch and DevelopmentRegulatory Affairs

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Apotex Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Apotex Inc. holds 50 active (52 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • VILOXAZINE HYDROCHLORIDEActive2024-11-07
  • OLANZAPINE FORM II USPActive2022-07-28
  • FLUTICASONE PROPIONATE USP (MICRONIZED)Active2020-12-30
  • BREXPIPRAZOLEActive2019-03-11
  • ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE USPActive2018-11-02
  • PALBOCICLIBActive2018-07-25
  • ELIGLUSTAT TARTRATE (1:0.5)Active2018-05-01
  • TOFACITINIB CITRATEActive2018-03-29
  • TREPROSTINIL DIETHANOLAMINEActive2017-10-05
  • TASIMELTEONActive2017-07-31
  • BULK EVEROLIMUSActive2016-10-27
  • POSACONAZOLEActive2016-03-31
  • AXITINIBActive2015-10-10
  • OLANZAPINE USPActive2015-06-22
  • DEXLANSOPRAZOLE ANHYDRATEActive2015-03-30
  • RUFINAMIDE USPActive2015-03-27
  • RIVAROXABANActive2014-12-31
  • VILAZODONE HYDROCHLORIDE BENZYL ALCOHOL MONOSOLVATEActive2014-07-18
  • DABIGATRAN ETEXILATE MESYLATEActive2014-03-28
  • TACROLIMUS USPActive2014-03-17
  • BUDESONIDE USPActive2013-11-01
  • DARIFENACIN HYDROBROMIDEActive2013-08-23
  • SIROLIMUS DRUG SUBSTANCEActive2013-02-27
  • ERLOTINIB HYDROCHLORIDEActive2013-01-22
  • ADEFOVIR DIPIVOXILActive2012-12-07
  • DESVENLAFAXINE SUCCINATE MONOHYDRATEActive2012-02-13
  • PALIPERIDONE USPActive2011-06-24
  • SITAGLIPTIN PHOSPHATE MONOHYDRATE USPActive2010-10-08
  • ABACAVIR SULFATE USPActive2010-03-19
  • MONTELUKAST SODIUM USPActive2010-01-29
  • ANASTROZOLE USPActive2009-12-01
  • MYCOPHENOLATE SODIUM USPActive2009-05-28
  • CEVIMELINE HYDROCHLORIDE HEMIHYDRATEActive2009-02-06
  • RIVASTIGMINE TARTRATEActive2008-12-04
  • OLANZAPINE USPActive2008-09-17
  • RISEDRONATE SODIUM HEMIPENTAHYDRATE USPActive2008-07-18
  • ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE USPActive2008-04-29
  • PAROXETINE HYDROCHLORIDE ANHYDROUS USPActive2008-03-18
  • MEMANTINE HYDROCHLORIDE USPActive2007-12-21
  • ALFUZOSIN HYDROCHLORIDE USPActive2007-06-08
  • ATOMOXETINE HYDROCHLORIDE USPActive2007-05-18
  • IBANDRONATE SODIUMActive2007-05-11
  • ARIPIPRAZOLE USPActive2006-11-13
  • MOEXIPRIL HYDROCHLORIDE USPActive2006-01-18
  • MIDODRINE HYDROCHLORIDE USPActive2005-06-30
  • ZIPRASIDONE HYDROCHLORIDEActive2005-02-03
  • ALENDRONATE SODIUM TRIHYDRATE USPActive2001-04-30
  • CYCLOSPORINE USP (BULK)Active1999-01-04
  • WARFARIN SODIUM CLATHRATE USPActive1995-03-15
  • DEFERIPRONEActive1994-04-12

Showing the 50 most relevant of 52 Drug Master Files (active first). The full list is in the FDA DMF list.

Excipient Drug Master Files

Apotex Inc. holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.

Registered manufacturing sites (1)

Physical sites registered with the US FDA and resolved to Apotex Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

50 FDA enforcement records linked to this company.

  • recall — Class II2026-10-07

    Failed dissolution specifications.

  • recall — Class II2026-09-02

    Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

  • recall — Class II2026-04-22

    Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

  • recall — Class II2026-03-25

    Lack of Assurance of Sterility

  • warning_letter2025-10-31

    FDA Warning Letter (drug product)

  • recall — Class II2025-10-08

    Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns

  • recall — Class II2025-10-08

    Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns

  • recall — Class II2025-07-02

    Lack of Assurance of Sterility

  • recall — Class II2025-07-02

    Lack of Assurance of Sterility

  • recall — Class II2025-07-02

    Lack of Assurance of Sterility

  • recall — Class II2025-06-11

    Defective Container: This recall is being initiated due to a leaking unit stored horizontally.

  • 4832025-05-09

    Validation lacking for sterile drug products

  • 4832025-05-09

    Written in-process control procedures

  • 4832025-05-09

    Complaint Handling Procedure

  • 4832025-05-09

    Computer control of master formula records

  • 4832025-05-09

    Investigations of discrepancies, failures

  • 4832025-05-09

    Absence of Written Procedures

  • 4832025-05-09

    Following/documenting laboratory controls

  • 4832025-05-09

    Cleaning / Sanitizing / Maintenance

  • 4832025-05-09

    Procedures for sterile drug products

  • 4832025-05-09

    Equipment to control conditions

  • recall — Class II2024-02-28

    CGMP Deviations: potential presence of Burkholderia cepacia complex

  • recall — Class II2023-12-06

    Failed Impurities/Degradation Specifications-Out of specification (OOS) results for the excipient Amadori Glucose adduct of Paroxetine

  • recall — Class II2023-12-06

    Failed Impurities/Degradation Specifications-Out of specification (OOS) results for the excipient Amadori Glucose adduct of Paroxetine

  • recall — Class II2023-12-06

    Failed Impurities/Degradation Specifications-Out of specification (OOS) results for the excipient Amadori Glucose adduct of Paroxetine

  • recall — Class II2023-12-06

    Failed Impurities/Degradation Specifications-Out of specification (OOS) results for the excipient Amadori Glucose adduct of Paroxetine

  • recall — Class II2023-05-17

    Presence of Foreign Substance: Glass splinter particle entrapped inside the pump ball seat rendered the pump inoperable.

  • recall — Class II2023-03-15

    Lack of sterility assurance: Cracks have developed in some of the units caps of Brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility.

  • recall — Class III2023-01-04

    Failed Stability Specifications: Out of specification for weight loss at the 18-month stability timepoint and projected weight loss of 21.1% at shelf life.

  • 4832022-09-14

    Procedures for sterile drug products

  • recall — Class II2022-07-27

    Failed dissolution specifications: OOS for dissolution at the 12-month stability time point.

  • recall — Class III2022-05-25

    Failed Dissolution Specifications: Sirolimus Oral Solution recalled due to lot RZ1598 exceeded the specification limit at the 14-month timepoint.

  • recall — Class II2021-04-14

    Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate

  • recall — Class I2021-02-17

    Labeling; Label Mixup; syringe barrels may containing markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength)

  • recall — Class I2021-02-17

    Labeling; Label Mixup; syringe barrels may contain markings for 100 mg/mL (corresponding to 100 mg/mL strength) instead of 150 mg/mL (corresponding to 120 mg/0.8mL strength)

  • recall — Class II2020-11-25

    Failed Dissolution Specifications: Out of specification for dissolution.

  • recall — Class II2020-06-24

    CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above acceptable intake levels

  • recall — Class II2019-11-20

    GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).

  • recall — Class II2019-11-20

    GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).

  • recall — Class II2019-11-20

    GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).

  • recall — Class II2019-11-20

    GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).

  • recall — Class II2019-11-20

    GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).

  • recall — Class II2019-11-20

    GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).

  • recall — Class III2019-11-06

    Presence of Foreign Tablets/Capsules: a single tablet of Pravastatin 40 mg found in bottle of Atorvastatin Calcium 40 mg.

  • recall — Class II2019-03-13

    Contraceptive Tablets Out of Sequence: Missing or incorrect tablet placement.

  • recall — Class II2018-06-13

    Presence of foreign substance: glass particles

  • recall — Class I2018-05-23

    Subpotent Drug: High Levels of Impurities Resulting in Decrease Potency

  • recall — Class I2018-05-23

    Subpotent Drug: High Levels of Impurities Resulting in Decrease Potency

  • 4832017-04-11

    Validation lacking for sterile drug products

  • 4832017-04-11

    Investigations of discrepancies, failures

For suppliers

Is this Apotex Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.